RM-MET / Metabolic and incretin signalling
Cagrilintide
Also known as: AM833
Grade describes the published research on the molecule. It is not a quality score, a safety score, or a release state.
What this is
An investigational long-acting amylin analog. Dose-finding human data has been published. Not a component of an approved drug.
Evidence position
Grade B. Human interventional evidence exists; no approved comparator. FDA has stated cagrilintide cannot be used in compounding under federal law. Note the frequent misspelling ‘cagrilitide’ in third-party listings — it is not a different material, but identity should always be confirmed against the record rather than the label.
What the record does not establish
Published research about a molecule is not a test of any particular vial. Identity, purity, strength and microbiological quality are established by lot-level analytical records tied to a matched sample — not by the literature, and not by the presence of an approved comparator.
Where a lot-level record exists it is published on the evidence page and linked from the product. Where it does not exist, the record says so.
Sources
- 01Dose-finding phase 2 trialPubMed
- Shows
- Human interventional data
- Does not show
- Investigational; no approved comparator
- 02FDA concerns with unapproved GLP-1 drugsU.S. Food and Drug Administration
- Shows
- Explicit regulator position on this molecule
- Does not show
- Not a quality assessment of any vial
External database index
LIVE DATABASE INDEX / SEPARATE FROM CURATED EVIDENCE
Records below come directly from public scientific databases. They help find relevant material, but do not affect the evidence grade until they are matched to the molecule and added to the curated source list.
PUBCHEM / IDENTITY
Cagrilintide
- CID
- 171397054
- Formula
- C194H312N54O59S2
- Mass
- 4409
PUBMED / FOUND RECORDS
- Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.The New England journal of medicine / 2025 Aug 14PMID 40544433 / DOI 10.1056/NEJMoa2502081
- Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis.BMJ (Clinical research ed.) / 2024 Jan 29PMID 38286487 / DOI 10.1136/bmj-2023-076410
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.The New England journal of medicine / 2025 Aug 14PMID 40544432 / DOI 10.1056/NEJMoa2502082
- Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.Lancet (London, England) / 2021 Dec 11PMID 34798060 / DOI 10.1016/S0140-6736(21)01751-7
- Weight management treatment in obesity.Medicina clinica / 2025 NovPMID 40865172 / DOI 10.1016/j.medcli.2025.107152
CLINICALTRIALS.GOV / FOUND RECORDS
- A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to DietRECRUITING / PHASE1 / Novo Nordisk A/SNCT07184086 / DIRECT intervention MATCH: Cagrilintide
- A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose WeightCOMPLETED / PHASE3 / Novo Nordisk A/SNCT05394519 / DIRECT intervention MATCH: Cagrilintide
- Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver DiseaseCOMPLETED / PHASE2 / Novo Nordisk A/SNCT06409130 / DIRECT intervention MATCH: Cagrilintide
- A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or ObesityCOMPLETED / PHASE1 / Novo Nordisk A/SNCT04940078 / DIRECT intervention MATCH: Cagrilintide
- The Role of the Amylin Analogue Cagrilintide in Bone MetabolismRECRUITING / PHASE1 / Novo Nordisk A/SNCT07010432 / DIRECT intervention MATCH: Cagrilintide